IL-37靶向TSLP减轻变应性鼻炎炎症反应的研究进展

目的变应性气道炎症的研究转向关注上皮损伤与下游炎症反应之间的关系而成为目前研究的前沿和热点。上皮衍生的细胞因子胸腺基质淋巴细胞生成素(thymic stromal lymphopoietin,TSLP)是变应性炎症疾病的主要开关，在变应性鼻炎(callergic rhinitis,AR)发病机制中起重要作用。白细胞介素 37（interleukin 37,IL 37）是IL 1家族新发现的细胞因子，通过降低循环和器官细胞因子水平而成为先天免疫和炎症反应的天然抑制因子。本文主要就IL 37靶向TSLP减轻AR炎症反应进行综述。

Department of Otorhinolaryngology Head and Neck Surgery, the Second Affiliated Hospital of Nanchang University, Nanchang 330006, China

Abstract:ObjectiveThe study of allergic airway inflammation turned to focus on the relationship between epithelial damage and downstream inflammatory response and became the frontier and hotspot of current research. Epithelial derived cytokine thymic stromal lymphopoietin (TSLP) is a major switch in allergic inflammatory diseases and plays an important role in the pathogenesis of allergic rhinitis. Interleukin (IL)-37, a newly discovered cytokine of the IL 1 family, is a natural inhibitor of innate immunity and inflammatory responses by reducing circulating and organ cytokine levels. This article reviews the alleviation of inflammatory response of allergic rhinitis by IL 37 targeting TSLP.MethodsResultsConclusion